Facial volume restoration and contour

Source date: 2026-11-08. Recorded in this review: November 10, 2026. Evidence: Sponsor conference reporting; open-label Phase 4 cohorts.

Allergan reported two prospective, multicenter studies in participants on stable GLP-1 doses. In HARMONY IN DIVERSITY cohort 2, 30 participants received hyaluronic-acid injectables, onabotulinumtoxinA and specified skin care; FACE-Q facial-appearance satisfaction rose 42.4 points on its 0–100 scale 30 days after toxin treatment. HALO's interim analysis covered 25 of 75 treated participants receiving HA injectables and reported a 39.6-point improvement at three months.

Both studies are open-label and single-arm. Satisfaction is a meaningful patient report, but expectation, participant selection, the incomplete HALO cohort and concurrent treatments limit causal interpretation. The multicomponent regimen cannot identify each component's contribution. Neither study demonstrates biological fat regeneration, superiority to another treatment or durable benefit after weight/dose changes.

Treatment-related events were described as mostly mild and nonserious; complete counts, denominators and posters were not recovered. This is sponsor conference reporting, with no new GLP-1-specific U.S. indication established.

Next: Full cohort, detailed harms and longer follow-up; release dates unverified.

Sources: AbbVie · source page.

Source date: 2026-11-04. Recorded in this review: November 10, 2026. Evidence: Peer-reviewed randomized study; full paper appraised.

A six-center Chinese study randomized 162 participants to a specific Novapath PLLA microsphere product or no treatment. In the full-analysis set, blinded assessors found at least one-grade improvement in both temples at six months in 85/106 (80.2%) versus 1/55 (1.8%); the difference was 78.4 percentage points (95% CI 68.1–85.9).

This was not an active-filler comparison. Participants and injectors were unblinded, and the sample was predominantly young Chinese women. Controls could receive treatment after month six, limiting later comparative durability claims. This product should not be silently equated with Sculptra or other PLLA formulations.

Any adverse events occurred in 30.2% versus 16.4%; diary-recorded local reactions affected 77.4% of treated participants, including predominantly palpable/nonvisible lumps or bumps. No related serious event was reported, but the sample cannot exclude rare harms. Visible temple correction does not prove restoration of native facial fat.

Next/U.S. status: No new U.S. authorization for this product/use or dated follow-up release was established.

Sources: Springer · article.

Coverage and remaining gaps: Focused/incomplete review; do not advance the full successful-check timestamp. Named CT.gov records and bounded discovery/paper searches were retrieved, but this is not complete worldwide registry, regulator, conference, device/procedure, safety or audio coverage. Retrieval continued after the scheduled 9 a.m. heartbeat; source dates are preserved. Fifteen named records, 38 recent registry records and 24 paper-search records retrieved; the broader registry query timed out. Full HALO/HARMONY posters, matching registrations, detailed harms and later follow-up remain gaps. The under-eye rhPDGF-BB estimated November start has not been verified as actual. Broad international procedure/material safety coverage remains incomplete.

Informal-source coverage: Searched indexed Reddit/Adipeau discussions and GLP-1 facial-change podcast/talk leads. Available descriptions and sponsored interviews did not supply a selected new specific rumor or controlled outcome; full recordings and the older promotional source chains remain incompletely appraised.

Full coverage record.

Source date: 2026-11-04. Recorded in this review: November 6, 2026.

First posted November 4, Lynch Regenerative Medicine’s NCT07914816 plans 75 adults aged 21–65 with moderate-to-severe infraorbital hollowing. Participants are randomized 1:1:1 to rhPDGF-BB/becaplermin 37.5 or 75 micrograms per under-eye region or saline, with optional same-assignment retreatment at week 8. A staggered sentinel cohort precedes broader enrollment.

Primary measures are treatment-emergent harms through 24 weeks after the final injection and at least one-grade improvement on a blinded hollow-severity scale 12 weeks after the final injection. Imaging volume, appearance/satisfaction, systemic exposure and antibodies are separate measures. The record’s description and structured fields differ about which treating personnel are unblinded; blinded outcome assessment is specified.

It remains not yet recruiting, with estimated November 9 start, September 30, 2027 primary completion and November 30 final completion. There are no efficacy, regeneration or safety results. Investigational under-eye injection must not be equated with approval of another becaplermin formulation or indication; no U.S. authorization for this use is established.

Sources: ClinicalTrials.gov · NCT07914816.

Source date: 2026-11-05. Recorded in this review: November 6, 2026.

First posted November 5, NCT07918443 plans 45 adults with Fitzpatrick skin types V/VI and midface volume deficit. This prospective U.S., open-label, single-arm study of saypha ChIQ measures treatment-emergent adverse/device events, injection reactions and ocular safety through 24 weeks after the last injection. Appearance and satisfaction are separate secondary outcomes. Optional touch-up is about two weeks after initial treatment.

The study addresses underrepresentation in the pivotal population; it has not begun recruiting and has no safety or efficacy results. Start January 2027 and primary/final completion July 2029 are registry estimates. An uncontrolled 45-person study cannot exclude rare serious complications or prove superiority.

Historical regulatory context, not new approval: FDA approved P250021 on June 12, 2026 for cheek augmentation/restoring midface deficits in patients over 21, with subcutaneous/supraperiosteal injection. FDA approved the post-approval protocol October 8 (S002). This new registration is not another approval or proof that this use is risk-free. Intravascular filler injection can have rare, serious vascular/visual harms. Actual commercial access was not verified.

Sources: ClinicalTrials.gov · NCT07918443; FDA · device approval record; FDA · device approval record; FDA · regulatory document.

Coverage and remaining gaps: focused_incomplete; Focused/incomplete: retrieved records and selective appraisal do not equal complete worldwide trial, paper, regulator, device/procedure, safety or informal-source coverage. Preserve full successful-check timestamps and baseline flags.; rhPDGF under-eye protocol contains differing blinding descriptions; no effect/safety outcome yet. Saypha FDA authorization/indication verified separately from actual availability; PAS is uncontrolled and not yet recruiting. HA-coated-thread NCT07916103 retrospectively registers completed2024–25study with no results; material biomarker or volume-regeneration effects cannot be inferred. Whole rare vascular-harm, fat-transfer retention and post-weight-loss series census unfinished.

Informal-source coverage: Original indexed Reddit/filler, grafting and injectable discussions plus professional-interview leads sampled. Personal retention experiences and promotional procedure claims not treated as formal new outcomes; no selected new rumor. Original recordings remain partial.

Full coverage record.

Source date: 2026-11-02. Recorded in this review: November 3, 2026.

First posted November 2, Galderma R&D's NCT07909421 plans 326 adults, randomized 1:1 to GP0112 injectable gel or Juvéderm Voluma XC for cheek augmentation and midface contour deficiency. The primary outcome is at least one-grade improvement on both sides of the face six months after the last treatment (initial injection plus any touch-up), assessed live by blinded evaluators using the Medicis Midface Volume Scale.

Both groups can receive an initial injection and optional touch-up. This is an active comparator study, not placebo-controlled; no efficacy, durability or rare-harm results are posted. The registry lists a Chinese site, not a new U.S. approval. It does not fully identify GP0112's commercial formulation, so other GP0112 studies or product labels must not be assumed interchangeable.

Recruitment has not begun in the registry. November 2026 start, January 2028 primary completion and August 2028 final completion are estimates; none promises a publication date.

U.S. status: No new U.S. authorization follows from this study or registration.

Next milestones: GP0112 cheek trial estimated start: 2026-11 (Registry estimate; not yet recruiting); GP0112 cheek trial primary completion: 2028-01 (Registry estimate; no public-result commitment).

Sources: ClinicalTrials.gov · NCT07909421.

Related findings, recorded once: A recombinant-enzyme umbrella study adds fat and cellulite subtracks (ClinicalTrials.gov · NCT07908953); Two small polynucleotide studies will measure neck lines and eye hollowing (ClinicalTrials.gov · NCT07912879).

Coverage and remaining gaps: focused_incomplete; do not advance full successful-check timestamp. Complete retrieval for these bounded queries is not complete worldwide clinical appraisal. Full international registry, conference, device/procedure, detailed safety and audio coverage remains incomplete.; GP0112 identity beyond injectable gel code and indication-specific U.S. status were not established by the Chinese registration. No superiority, rare vascular-event risk or durability claim follows.; Full volume-retention, post-weight-loss comparative series and long-term biostimulator safety census incomplete; prior Belotero launch forecasts not generalized to actual availability.

Informal-source coverage: Reddit injectable/filler discussions sampled; older PN lip-series posts describe small studies, not new comparative volume-regeneration efficacy. No selected new development rumor; complete interview/audio coverage incomplete.

Full coverage record.

Source date: 2026-10-29. Recorded in this review: October 30, 2026. Event/approval date: 2026-10-27.

The October 29 update to RAD-NLF-CN003 (NCT07856797) changes the study to recruiting and records an actual October 27, 2026 start, replacing an estimated October start. It plans 163 Chinese adults with moderate-to-severe nasolabial folds in an open-label, single-group post-market follow-up study.

Participants receive bilateral RADIESSE calcium-hydroxylapatite treatment with an optional month-one touch-up and follow-up to 24 months after the last treatment. The primary endpoint is at least one-point improvement in both folds on the investigator-rated Wrinkle Severity Rating Scale at month 6. Patient appearance and delayed safety need separate assessment.

There are no results, blinded comparator or proof of superior durability versus another filler. The record contains conflicting explanatory directions for the secondary GAIS scale; do not treat those descriptions as validated numerical results. Estimated primary completion August 2027 and final completion February 2029 are not promised publications. A Chinese study start is distinct from a new U.S. indication.

U.S. status: This registry update establishes no new U.S. approval or indication.

Next milestones: RADIESSE China primary completion: 2027-08 (Registry estimate; month precision); RADIESSE China final completion: 2029-02 (Registry estimate; month precision).

Sources: ClinicalTrials.gov · NCT07856797.

Coverage and remaining gaps: focused_incomplete; do not advance full successful-check timestamp. Focused incomplete appraisal only; complete retrieval for these bounded queries is not complete worldwide clinical review. Full successful-check timestamps remain unchanged. Independent national registries, every conference appendix, all device/procedure safety and all podcast audio/comments remain incomplete.; RADIESSE secondary GAIS explanatory directions conflict; no results to interpret.; Actual nationwide Belotero launch and complete filler rare-event/long-term surveillance remain unverified.

Informal-source coverage: Targeted original Reddit, interview and podcast leads sampled. Removed posts, local clinic availability and self-injection anecdotes do not establish new comparative results or authorized nationwide launch. No noteworthy new development rumor selected.

Full coverage record.

Source date: 2026-10-23. Recorded in this review: October 27, 2026.

First posted October 23, NCT07891767 plans 300 adults of Chinese origin who already received midface Sculptra 11–12 months before entry. Medical-record review plus another 12 months of prospective follow-up will cover 24 months after the original treatment; this is not a newly randomized two-year efficacy trial.

The registry tracks related adverse-event onset, duration and intensity; focused examinations; patient complaints and safety satisfaction; aesthetic improvement and perceived effectiveness. It has no active or sham comparator. Selection of previous recipients and the completeness of old records can affect estimates of delayed events and durability.

The registry lists recruiting, but the October 2026 start remains estimated. Primary/final completion is estimated for April 2028. There are no results. This adds a specific longer-follow-up program, not a new FDA midface indication, proof of better safety than another filler or restoration of skin laxity distinct from volume.

U.S. status: This Chinese observational registry does not establish a new U.S. indication or authorization.

Next milestones: Sculptra Chinese long-term cohort primary and final completion: 2028-04 (Registry estimate; month precision).

Sources: ClinicalTrials.gov · NCT07891767.

Coverage and remaining gaps: focused_incomplete; do not advance full successful-check timestamp. Worldwide completion is not established: CTIS, ChiCTR/jRCT and other national registries, every indexed article, every conference poster and unindexed social/audio sources were not exhaustively appraised. Keep the full successful-check timestamp unchanged.; No complete review of every filler, fat-graft, implant and facial-contour device program or delayed-event surveillance source.; Belotero Volume October 14 and Intense December 1 launch dates in prior sponsor context were forecasts; clinic advertisements alone did not verify nationwide availability.

Informal-source coverage: scope: Original sponsor index, indexed Reddit and aesthetic interview/podcast leads sampled.; status: No selected new development rumor; marketing and local clinic availability do not prove nationwide product launch or comparative outcomes.; limitations: No exhaustive clinic rollout or full audio/transcript census.

Full coverage record.

Source date: September 14, 2026; recovered during the October 9 check. This is older U.S. access context, not a newly issued October approval.

Merz forecasts commercial availability on October 14, 2026 for Belotero Volume (+) and December 1 for Belotero Intense (+). FDA approved Volume on May 19 for specified deep midface volume/contour implantation in adults 22+, already recorded here. FDA's original P250016 documents Intense approval on July 9, 2026, for submucosal/subcutaneous lip augmentation in adults over 21. Later manufacturing/assay supplements are not new anatomical indications.

Interpretation and safety: A launch forecast does not establish current local inventory, superior appearance or better benefit after weight loss. Marketing claims of regeneration and tissue mimicry do not prove new facial-fat growth; these are fillers. Local swelling, bruising, pain and nodules and uncommon intravascular blindness/stroke/necrosis risks remain separate from approval. Complete pivotal efficacy/safety tables and post-approval long-term outcomes were not newly appraised. Next: verify actual launch after each forecast date, preserving formulation, site and age restrictions.

Original Merz announcement; FDA Intense original approval; FDA Volume original approval.

Remaining gaps: Read the current assigned topic and canonical scope/state. Named original registry records refreshed; all pages of broad ClinicalTrials.gov discovery for September 5–October 9 were retrieved (107 records, with incidental matches excluded). This honors the seven-day overlap from the saved September 12 full successful check.; Europe PMC original-literature discovery again returned HTTP 503. Targeted primary publisher, sponsor and conference searches were performed, but the worldwide paper/regulator/procedure and original-audio census remains incomplete. Preserve last_successful_check_utc.; Macrofat NCT07805889 recruiting 400 and GLP1-Radiesse recruiting/no results retain status. HArmonyCa completion and new Facetem/Radiesse registrations already recorded October 6. No new comparative efficacy selected.; Full new-filler FDA/overseas inventory, precise launch inventory, rare delayed harms and post-weight-loss randomized efficacy remain incomplete. Existing HA-collagen reporting discrepancy not resolved.

Informal-source coverage: October9 https://www.reddit.com/r/PlasticSurgery/comments/1x1lv4i/fat_grafting_failed_renuva_vs_sculptra_for/ describes personal graft-survival experience and requests alternatives; not a formal trial or general incidence. Recent Secret Services podcast descriptions and saved Lufkin/Durairaj episode do not supply a verified new named-program claim; recordings/transcripts not appraised. Adipeau promotion remains distinct from its already saved uncontrolled pilot. No new rumor selected.

Full coverage record.

Source/event date: October 2, 2026 first registry posting.

DEFINE (NCT07855224) is a planned prospective, uncontrolled post-market follow-up of calcium-hydroxylapatite Facetem S for moderate-to-severe nasolabial folds. It plans 100 adults, with France/Spain sites, optional touch-up and follow-up to 12 months. The primary endpoint is at least one WSRS grade of improvement at week 12, or week 16 after touch-up. It is not yet recruiting; start January 2027, primary completion April 2028 and final January 2029 are estimates. No outcomes or harms are posted. Wrinkle-fold correction does not establish regained facial fat, durable tightening or superiority to other fillers. This registry does not establish a U.S. authorization for this exact product. Next: actual start and results; no publication date verified.

Original registry.

Source date: October 5, 2026 registry posting. Reported actual completion: September 3, 2026.

NCT07032597 now lists a completed randomized, assessor-masked Phase 3 study in 252 adults at Chinese sites. HArmonyCa Lidocaine is compared with Restylane Perlane Lidocaine for midface-volume correction, with an optional touch-up. The primary effectiveness measure is at least one grade improvement on the Mid-Face Volume Deficit Scale at month six; adverse events are also primary outcomes. No results are posted, so noninferiority/superiority, duration and comparative harms remain unknown. Volume correction is distinct from laxity treatment or regenerated adipose tissue. The registry update supplies no new U.S. authorization or routine-availability conclusion. Next: comparative outcome and safety publication; timing unknown.

Original registry.

Source/event date: October 5, 2026 first registry posting.

NCT07856797 plans an uncontrolled study of RADIESSE for moderate-to-severe nasolabial folds in 163 Chinese adults, with optional touch-up and up to 24-month follow-up. The primary endpoint is at least one WSRS grade improvement in both folds at month six after final treatment. It is not yet recruiting; start October 2026, primary completion August 2027 and final February 2029 are estimates. This is a new study of an existing filler, not a new U.S. approval or a demonstrated advantage in durability or safety. It will not directly compare fillers, establish restored facial fat or distinguish filling from tightening. Next: actual start, long-term safety/degradation findings and results publication; release date unknown.

Original registry.

Source date: 2026-09-08. Event date: 2026-09-08. Evidence: trial-registry record; new-to-watch study.

A newly registered cohort proposes ultrasound measurement of fat-graft persistence after facelift, alongside complications and patient satisfaction. NCT07805889: prospective observational registry, 400 planned adults, recruiting. First posted September 8 but lists an actual January 1, 2023 start. Primary outcome is 12-month ultrasound-derived graft volume relative to postoperative month 1; it is not the percentage of injected fat surviving. Primary completion estimated December 10, 2026; final completion March 1, 2027.

Limitations: Retrospective registration, no randomized comparator and combined facelift/fat-grafting treatment. The record still contains unfinished scoring/manual wording. It excludes planned major weight loss or expected weight change above 10%, limiting applicability during active weight loss.

Safety: Planned outcomes include nodules, oil cysts, infection, contour irregularities, fat necrosis, vascular events and revisions; no outcome or safety results posted.

U.S. status: Registration does not establish a new FDA authorization or superior surgical technique.

Next milestone: Verify registry consistency and posted results; December 2026/March 2027 are completion estimates, not promised publications.

Primary facial-fat-grafting registry.

Source date: 2026-09-14. Event date: 2026-09-14. Evidence: peer-reviewed human pilot plus separate laboratory experiments; full text appraised.

A small uncontrolled study found regional facial-volume changes after a topical botanical formulation; it does not establish regenerated facial fat. NCT04769193 / Adipeau-001: 35 participants, 31 women, mean age 46.5, six months of KPRE plus long-chain fatty-acid cream. Median gains at six months were 1.48 and 1.39 cm³ for left/right facial halves; losses in other regions were 0.72 and 0.52 cm³. This September publication reports a study conducted in 2021–2022.

Limitations: Open-label, single-site, no vehicle comparison; target enrollment was 75. The prespecified elasticity measurement was abandoned for methodological reasons. Surface imaging cannot isolate fat from hydration, weight or dermal changes, or prove adipogenesis. Adipeau partly funded the work; an author is an employee and patent holder.

Safety: No usable clinical adverse-event table was located in the full paper; do not infer a demonstrated safety advantage.

U.S. status: Cosmetic-formulation research, not new FDA approval for restoring facial fat.

Next milestone: Controlled replication and post-treatment durability undated.

Original full text; Original publication; Trial registry.

Galderma's NCT06351358 now has a peer-reviewed report, published online November 17, 2025, in the May 2026 journal issue. It enrolled 41 people; 35 completed, predominantly women (39/41; mean age 58.9). Participants received poly-L-lactic acid (Sculptra) plus either Restylane Lyft or Contour, with follow-up through nine months after the last Sculptra treatment. Appearance, hydration, radiance and satisfaction improved; no treatment-related adverse events were reported. This was an open-label, uncontrolled, industry-funded study, so it cannot isolate each product's contribution or establish superiority over another approach. Primary paper

The earlier sponsor summary reported 85.7% saying their face looked less gaunt at nine months. That is a participant rating, not measured replacement of 85.7% of lost facial fat. Its N=35 refers to the final cohort rather than all enrollment; the paper is the preferred account. Dated sponsor release

Next: no dated randomized comparison or longer-term results release was verified. Watch controlled comparisons, diverse populations, multi-year durability and evidence on the best timing relative to weight stabilization.

Follow hyaluronic-acid products, poly-L-lactic acid, calcium-hydroxylapatite and other formally studied materials, including combinations and retreatment strategies. FDA approvals are product-, anatomical-site- and indication-specific; approval of one filler does not establish approval of every use or a combination protocol. FDA's approval database links the clinical evidence and labeling for each new indication, and warns that an approved product may not currently be marketed. FDA approval reference

Galderma's first-half-2026 update reports new U.S. Restylane indications and overseas expansion, including Restylane Shaype chin augmentation in Thailand and Sculptra body indications in Australia. These are geographic development signals, not evidence that every formulation or site is approved in the U.S. Specific labels and comparative studies should be checked for each subsequent update. No dependable next filing or decision date was found. 2026 sponsor update

Belotero Volume (+) Lidocaine — FDA approval on May 19, 2026. PMA P250020 authorizes deep subcutaneous and/or supraperiosteal injection to improve mid-face volume deficits or contour deficiencies in adults 22 and older. This is an older regulatory baseline addition, not September news. It does not establish superiority over other fillers, approval at every anatomical site, or a specific advantage after weight-loss medication. Actual retail/clinical launch availability was not independently checked; indication-specific labeling and the general filler risks above remain relevant.

An older randomized Chinese trial, ChiCTR-IOR-14005599, assigned 63 facial-asymmetry patients to three fat-processing methods, assessing volume with 3-D scans through 12 months. Cotton-pad filtration retained more volume than centrifugation or sedimentation, but incomplete follow-up limited inference. This provides a useful model for assessing innovations: objective volume and durability, not only selected photographs. Facial asymmetry data do not automatically establish results after GLP-1-associated weight loss. Primary trial

Monitor prospective comparisons of preparation, injection, imaging and formally studied cellular adjuncts. Track revision procedures, unevenness and long-term changes alongside retention. No firm next major readout date was verified; claims that a processing method guarantees permanent graft survival require human follow-up.

FDA identifies accidental intravascular injection as a serious filler risk, potentially causing tissue necrosis, stroke or blindness; other adverse effects can appear months or years later. Small uneventful studies cannot rule out uncommon harms. Later safety analyses, reversibility and removal outcomes belong in the watchlist alongside efficacy. FDA safety information